share_log

HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14

Moomoo 24/7 ·  Mar 6 06:49

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Cardiff Oncology (NASDAQ:CRDF) with a Buy and raises the price target from $12 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment